Resources
Insights
Report · Why 60% of drug launches fail
Customer stories
Research studies
Book a demo
How commercial and medical leaders use mama health to anchor launch decisions in real-world patient evidence — market by market, country by country.
5 markets live. 100+ dermatologists enrolled. One KPI'd patient journey — across DE, US, UK, JP, and CA. A top-10 global pharma pressure-tested their patient journey against quantitative patient data, rewrote where evidence diverged from assumption, and built a digital companion programme the field can actually plan against.
"What patients said they needed in Berlin is shaping what patients see in Tokyo."
By working with mama health, we can leverage AI-powered, real-time aggregate data collection to integrate the unbiased patient perspective into our business strategy — unlocking valuable, actionable insights, continuously measuring the outcomes and impact of our initiatives.
A first-in-category neurology launch, anchored in patient evidence from market one.
11 European markets. 100,000+ patient data points generated. Now embedded at European leadership level. A top-20 biopharma entered a rare neurology indication with no prior commercial playbook. One pilot became the foundation for a pan-European patient intelligence contract that is now how leadership decides where to act.
After 22 years in healthcare, I've learned that the real insight lies in the last mile of the patient journey. mama health captures that like never before.
What life science partners are unlocking when they build on mama health.
Every customer story on this page follows the same shape. Pilot in one market. Validate the journey. Scale across the portfolio.
Take an existing patient journey, KOL-built or otherwise. Pressure-test it against quantitative data from real patients in the disease.
Where assumption and evidence diverge, the journey is rewritten. KPIs are placed on every stage so stakeholders can plan against it.
Findings carry into commercial, medical and field teams via cross-functional sessions, MSL onboarding, and partner asset integration.
Pilots prove the model. Engagements then expand market by market, with patient voice from each one feeding a single, unified instrument.
Filter by therapy area, region or use case. New engagements added as they become public.
